The estimated Net Worth of Stephen A. Tullman is at least $209 Tysiąc dollars as of 4 October 2018. Stephen Tullman owns over 7,100 units of Aclaris Therapeutics Inc stock worth over $209,399 and over the last 9 years Stephen sold ACRS stock worth over $0.
Stephen has made over 4 trades of the Aclaris Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Stephen bought 7,100 units of ACRS stock worth $99,400 on 4 October 2018.
The largest trade Stephen's ever made was buying 26,700 units of Aclaris Therapeutics Inc stock on 6 April 2018 worth over $441,618. On average, Stephen trades about 5,831 units every 23 days since 2015. As of 4 October 2018 Stephen still owns at least 177,457 units of Aclaris Therapeutics Inc stock.
You can see the complete history of Stephen Tullman stock trades at the bottom of the page.
Stephen's mailing address filed with the SEC is C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN, PA, 19355.
Over the last 9 years, insiders at Aclaris Therapeutics Inc have traded over $101,608,525 worth of Aclaris Therapeutics Inc stock and bought 10,163,038 units worth $66,383,599 . The most active insiders traders include Braden Michael Leonard, Capital Management, Llc Kol... oraz Llc Fmr. On average, Aclaris Therapeutics Inc executives and independent directors trade stock every 17 days with the average trade being worth of $111,818. The most recent stock trade was executed by Kevin Balthaser on 1 September 2024, trading 1,000 units of ACRS stock currently worth $1,180.
aclaris therapeutics, inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. aclaris is focused on market segments with no fda-approved medications or where treatment gaps exist. aclaris was founded by dermatologists and is led by a team with extensive experience in developing and commercializing dermatologic treatments.
Aclaris Therapeutics Inc executives and other stock owners filed with the SEC include: